Literature DB >> 34678221

Cathepsin C inhibition as a potential treatment strategy in cancer.

Brice Korkmaz1, Anne-Sophie Lamort2, Roxane Domain3, Céline Beauvillain4, Artur Gieldon5, Ali Önder Yildirim2, Georgios T Stathopoulos2, Moez Rhimi6, Dieter E Jenne7, Ralph Kettritz8.   

Abstract

Epidemiological studies established an association between chronic inflammation and higher risk of cancer. Inhibition of proteolytic enzymes represents a potential treatment strategy for cancer and prevention of cancer metastasis. Cathepsin C (CatC) is a highly conserved lysosomal cysteine dipeptidyl aminopeptidase required for the activation of pro-inflammatory neutrophil serine proteases (NSPs, elastase, proteinase 3, cathepsin G and NSP-4). NSPs are locally released by activated neutrophils in response to pathogens and non-infectious danger signals. Activated neutrophils also release neutrophil extracellular traps (NETs) that are decorated with several neutrophil proteins, including NSPs. NSPs are not only NETs constituents but also play a role in NET formation and release. Although immune cells harbor large amounts of CatC, additional cell sources for this protease exists. Upregulation of CatC expression was observed in different tissues during carcinogenesis and correlated with metastasis and poor patient survival. Recent mechanistic studies indicated an important interaction of tumor-associated CatC, NSPs, and NETs in cancer development and metastasis and suggested CatC as a therapeutic target in a several cancer types. Cancer cell-derived CatC promotes neutrophil recruitment in the inflammatory tumor microenvironment. Because the clinical consequences of genetic CatC deficiency in humans resulting in the elimination of NSPs are mild, small molecule inhibitors of CatC are assumed as safe drugs to reduce the NSP burden. Brensocatib, a nitrile CatC inhibitor is currently tested in a phase 3 clinical trial as a novel anti-inflammatory therapy for patients with bronchiectasis. However, recently developed CatC inhibitors possibly have protective effects beyond inflammation. In this review, we describe the pathophysiological function of CatC and discuss molecular mechanisms substantiating pharmacological CatC inhibition as a potential strategy for cancer treatment.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Inflammation; Inhibitor; Neutrophil; Protease; Treatment strategy

Mesh:

Substances:

Year:  2021        PMID: 34678221     DOI: 10.1016/j.bcp.2021.114803

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery.

Authors:  Daan G J Linders; Okker D Bijlstra; Laura C Fallert; Denise E Hilling; Ethan Walker; Brian Straight; Taryn L March; A Rob P M Valentijn; Martin Pool; Jacobus Burggraaf; James P Basilion; Alexander L Vahrmeijer; Peter J K Kuppen
Journal:  Mol Imaging Biol       Date:  2022-08-24       Impact factor: 3.484

2.  A View on Cathepsin C as a Target for Therapy in AAV.

Authors:  Renate Kain; Maja C Nackenhorst
Journal:  J Am Soc Nephrol       Date:  2022-04-08       Impact factor: 14.978

3.  Evolutionary Analysis of Dipeptidyl Peptidase I.

Authors:  Nina Varda; Marko Novinec
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

4.  Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.

Authors:  Genhao Zhang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.